DataMEDS AI, Inc. (NASDAQ:MEDS) announced on September 21, 2026, that it had launched a new corporate website, www.DataMedsAI.com. The Tampa-based Health IT company said the website follows the closing of its Helomics Corporation acquisition and the settlement of litigation connected with its May 11, 2023 acquisition of Wellgistics, LLC.
#Website follows corporate developments
DataMEDS said it acquired Helomics Corporation’s artificial intelligence Cancer Diagnostics Lab from Axe Compute. The company also said the litigation settlement extinguished ~$19 million in liabilities from its balance sheet and led to the retirement of 364,099 common shares.
Gerald E. Commissiong, DataMEDS’ Interim Co-CEO, said the website introduces new branding for the parent company. He also said management had shifted its marketing efforts towards artificial intelligence and intended to build organic website traffic and attract earned media interest.
#Health Lives Here application
Commissiong said DataMEDS was poised to launch its Health Lives Here consumer application. He said the company intended to soft launch the app in short order. The announcement did not provide a launch date or state that the soft launch had been completed.
DataMEDS says the Health Lives Here mobile application incorporates the EinsteinRx™ artificial intelligence platform and PharmacyChain™, a blockchain-enabled smart contracts platform. Its Corexa Health subsidiary provides pharmacy and pharmacy services, including the distribution of products developed by Tollo Health, LLC.
#Business plans and proposed transaction
The company describes its operations as combining technology, pharmacy, pharmaceutical-adjacent and telemedicine business units. The release also refers to plans to expand into telemedicine and diagnostic laboratory services.
DataMEDS also identified a proposed transaction involving DataVault AI Inc. (NASDAQ:DVLT), Scilex Holding Company, EOS Holdings and HealthBridge Advisors. The release states that applicable closing conditions, stockholder approval and other required approvals may need to be satisfied or waived.
#Forward-looking statements and risks
DataMEDS said its forward-looking statements are based on management’s current expectations and are not predictions of actual performance. The company identified uncertainties involving its ability to increase organic website traffic and attract earned media interest, as well as the completion of transaction conditions and receipt of required approvals.
The release also cited risks related to integrating and developing its telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies. Other matters identified included maintaining compliance with Nasdaq listing standards, liquidity, capital resources and the ability to fund operations.
#Key Takeaways
- DataMEDS AI announced the launch of www.DataMedsAI.com on September 21, 2026.
- The announcement followed the closing of the Helomics Corporation acquisition and a litigation settlement related to Wellgistics.
- DataMEDS said the settlement extinguished ~$19 million in liabilities and resulted in the retirement of 364,099 common shares.
- Interim Co-CEO Gerald E. Commissiong said the company intended to soft launch the Health Lives Here application in short order, but no launch date was provided.
- The release identified conditions, approval requirements and operational risks linked to proposed transactions and future plans.
Original source: Read original article